Clearly, by holding 232k shares, Missling is of the WGT mindset, especially after delivering astonishingly successful "P3" AD results that MET ALL ENDPOINTS, where patients actually improved (according to the Odds Ratios). Nothing "fumbled" about an impressively successful AD trial that the MABs can't touch. Then to follow that up with more impressive data from Rett trials, where patients improved more the longer they were dosed.
As Missling moves toward NDA submissions and preparations for commercialization, he knows just how successful and profitable Anavex and blarcamesine will be once approvals are received... soon!
News 
Market Data 
Discover 
